APASL 2026 22 - 25 April 2026

Semaglutide demonstrates efficacy in improving liver fibrosis across diverse subpopulations in part 1 of the ESSENCE trial outcomes in Asian and non-Asian populations

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.
Keywords
MASH
Congress oral presentation
GLP-1 RA
Semaglutide
PHASE 3 (RCT)